Rate My Professor Christine Kempton

Dr. Kempton's research specializations include complications of hemophilia and novel treatments of congenital and acquired bleeding disorders, with emphasis on health services and outcomes research focused on hemophilia and other rare bleeding disorders. Her sponsored research projects encompass a cross-sectional analysis of cardiovascular disease in the hemophilia population, the BH29884-ACE910 phase III clinical trial, Community Counts public health surveillance for bleeding disorders, and post-marketing safety evaluation of Obizur for acquired hemophilia A. She received the Young Investigator Award from the International Society of Thrombosis and Haemostasis in 2003 and participated in the American Society of Hematology Clinical Research Training Institute. Key publications are 'Race, Ethnicity, and Hemophilia: A Scoping Review' (2023), 'Defining the impact of immune tolerance induction on health care use and patient-reported outcomes in persons with severe hemophilia A' (2024), 'Management of comorbidities in haemophilia' (2021), and 'Inhibitors in previously treated patients: A review of the literature' (2010). Her scholarly work has notably influenced the field of bleeding disorder management.